|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Open Label Extension Study to Evaluate the Safety, Tolerabilityand Cognitive Effects of VEL015 (Sodium Selenate) in Patientswith Alzheimer’s Disease
A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and the Biological and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Mild to Moderate Alzheimer’s Disease – a Pilot Study
100 Clinical Results associated with Velacor Therapeutics Pty Ltd.
0 Patents (Medical) associated with Velacor Therapeutics Pty Ltd.
100 Deals associated with Velacor Therapeutics Pty Ltd.
100 Translational Medicine associated with Velacor Therapeutics Pty Ltd.